Gauge, pain and flow rate
Skin thickness at the standard injection sites is approximately two millimetres in adults and varies remarkably little with body mass. That single finding is why short…
Dosing
Page 13 of 31 of this archive, newest first.
STEP 2 was built to answer the stopping question, and it did
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
How a correct calculation becomes a wrong dose
Almost every case involves a change — a new vial, a new syringe size, a new supplier — carried forward with an old number.
Italy pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Singapore pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Is liraglutide better than mazdutide, or differently balanced?
What adding GIP activity does, on the current evidence, and what remains unresolved.
Retained gastric contents, and how a small finding became a large argument
A drug that delays gastric emptying complicates the assumption behind every fasting instruction in perioperative medicine. The professional bodies have moved twice on this…
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Ireland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Escalating onto a rising curve
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
The mechanism behind the mechanism
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
Switzerland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Portugal guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The arithmetic of a step: what doubling a dose actually asks of you
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
Gastric emptying is a mechanism, not a side effect
The central effects are not a bonus. On the current evidence they are the principal mechanism of weight loss.
Storage after reconstitution, and the evidence behind the numbers
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
The eighteenth month, and the conversation that should have happened in the third
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
What the trials counted as intolerance
Trial discontinuation figures are a floor, not an estimate: trial populations are supported in ways ordinary patients are not.